Held-out trials, OS hazard ratio of higher- against lower-risk half, geometric mean over six trials
Split each held-out trial's patients at the method's median predicted risk and estimate the overall-survival hazard ratio of the higher-risk half against the lower-risk half, then take the geometric mean over six trials.
Overview
An explanatory profile has not yet been reviewed for this record.
Consult the linked sources for architecture or protocol details. Missing evidence is not evidence of a missing capability.
7 recorded evaluations, 7 metric rows. A comparison chart has not yet been validated for these results. The table retains the individual findings and their sources.
Results
Results are available, but no reviewed comparison panel is linked in this release.
All evaluations
7 evaluations · 7 results. Different protocols are not a single leaderboard.
Protocol: Held-out trials, OS hazard ratio of higher- against lower-risk half, geometric mean over six trials · Dataset subset: Six held-out trials with overall survival
Sorted by Hazard ratio (hazard ratio, higher-risk half against lower-risk half at the median predicted risk, overall survival, Cox stratified by treatment arm, Efron ties, full follow-up; equal-trial geometric mean over six trials) (higher is better). The best value in each column is highlighted. Decimals are rounded for display; each value links to the printed value and its source.
| Tested configuration | Hazard ratio (hazard ratio, higher-risk half against lower-risk half at the median predicted risk, overall survival, Cox stratified by treatment arm, Efron ties, full follow-up; equal-trial geometric mean over six trials) |
|---|---|
| Ladon + clinical covariates, summed standardised risk scores (held-out trials)Evaluation | 2.15 (best in column) |
| Ladon, survival mid-trained, ridge Cox fitted on TCGA and other trials (held-out trials)Evaluation | 1.97 |
| BulkFormer 147M (Ladon report comparator)Evaluation | 1.63 |
| Clinical covariates encoded by BMRetriever-7B (Ladon report baseline)Evaluation | 1.61 |
| BulkRNABert, published Hugging Face checkpoint (Ladon report comparator)Evaluation | 1.55 |
| Differential gene expression signature (Ladon report)Evaluation | 1.52 |
| Isoform TPM features (Ladon report)Evaluation | 1.29 |
All 7 result rows with coverage, uncertainty and sources
Filter evaluations
Applied filters: All linked evaluations
Source checking is not independent reproduction. Release 2026-11-21-c8bea25e5abb.
Methods and evaluation design
Procedure, tasks and evaluated configurations
Recorded evaluations
Each evaluation records what was tested and under which conditions.
- BulkFormer, held-out trials OS hazard ratio
- BulkRNABert, held-out trials OS hazard ratio
- Clinical covariates (BMRetriever), held-out trials OS hazard ratio
- Differential gene expression, held-out trials OS hazard ratio
- Ladon, held-out trials OS hazard ratio
- Ladon + clinical covariates, held-out trials OS hazard ratio
- TPM · matched TCGA, held-out trials OS hazard ratio
Baseline coverage
Reference methods help show what a model adds beyond simple controls. We track a null control and a conventional method for each protocol.
0 of 2 active baseline roles have published Rewire measurements in this release. Measurements on a selected protocol do not establish coverage of an entire suite.
No execution recipe linked to this protocol. Recipe availability does not establish a completed evaluation.
- Author-reported evaluations
- 7
Literature evidence is not a Rewire measurement. Executed but unpublished runs and private review status are not included.
Null control
Proposed control: requires review
Select a task-valid null control after reviewing inputs and metric
Protocol-specific applicability, permitted inputs, access, split, evaluator and execution requirements need review before implementation or execution.
This is a suggested selection rule, not a validated method or a measured score.
Conventional reference
Proposed control: requires review
Select an upstream conventional reference after reviewing the full protocol
Protocol-specific applicability, permitted inputs, access, split, evaluator and execution requirements need review before implementation or execution.
This is a suggested selection rule, not a validated method or a measured score.
Protocol coverage CSV (gzip) · Model evaluation matrix (gzip) · Source table (gzip) · Release and checksums (gzip)
Coverage is derived from release 2026-11-21-c8bea25e5abb. Source citations describe the original records; they do not validate an unreviewed baseline proposal. No results have been generated by this audit.
Run instructions
No runnable recipe has been reviewed for this protocol. Dataset access, model requirements, licences and compute requirements must be checked against its sources before execution.
Evidence
Source checking verifies the cited claim or transcription. It does not establish independent reproduction.
Evidence table
Inspect claims, sources and review details
Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.
One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.
0 evidence rows matching the loaded filters
| Property and statement | Original source and location | Review and provenance |
|---|
No evidence rows match these filters. Choose another scope or clear the search.
Sources and history
Release 2026-11-21-c8bea25e5abb · Record review: source checked
1 source record and release history
- Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF) · Original source · Zenodo record 24157116 (version DOI 10.5281/zenodo.24157116; concept DOI 10.5281/zenodo.24157115), file Ladon-An-RNA-Foundation-Model-for-Predicting-Patient-Outcomes.pdf, 47 pages, dated 12 November 2026
Technical metadata and record identifiers
Technical metadata for this record is tracked under stable ID ladon-20261115-protocol-trials-os-hazard-ratio.
Source locator: Figure 3 (page 7) and caption; pages 13 and 14, Methods 'Survival in held-out trials'
Related records
- evaluates task: Survival prognosis from pretreatment bulk RNA-seq
- uses data: Six held-out trials with overall survival
- used in: Six held-out trials with overall survival
- assessment: BulkFormer, held-out trials OS hazard ratio
- assessment: BulkRNABert, held-out trials OS hazard ratio
- assessment: Clinical covariates (BMRetriever), held-out trials OS hazard ratio
- assessment: Differential gene expression, held-out trials OS hazard ratio
- assessment: Ladon, held-out trials OS hazard ratio
- assessment: Ladon + clinical covariates, held-out trials OS hazard ratio
- assessment: TPM · matched TCGA, held-out trials OS hazard ratio